These 3 Risky Stocks Could Be Sitting on 100% UpsideMarket Beat·Sep 7 at 03:35 PMRCAT-1.73%SLSR+1.62%
Taysha Gene Therapies grants new hires 314,000 RSUs, 92,400 options at $5.7 strikePUBT·Sep 4 at 12:01 PMTSHA+2.88%
Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentationPUBT·Aug 31 at 06:26 PMTSHA+2.88%
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from BrokeragesMarket Beat·Aug 18 at 08:29 AMTSHA+2.88%
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's WhyMarket Beat·Aug 13 at 07:40 PMTSHA+2.88%
Gil Blum Reaffirms Buy Rating on Taysha Gene Therapies, Maintains $12 Price Target Amid De-Risking Clinical MilestonesTip Ranks·Aug 12 at 10:45 AMTSHA+2.88%
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% UpsideTradingView·Aug 12 at 10:20 AMTSHA+2.88%
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPSMarket Beat·Aug 11 at 08:11 PMTSHA+2.88%
TSHA: TSHA-102 trials completed dosing; topline data and FDA feedback expected in 1H 2027Quartr·Aug 11 at 08:08 PMTSHA+2.88%
Taysha Gene Therapies grants new hire 144,000 RSUs, 92,400 stock options priced at $5.78PUBT·Aug 7 at 12:02 PMTSHA+2.88%
Taysha Gene Therapies to report Q2 results, host corporate update call and webcastPUBT·Aug 4 at 08:00 PMTSHA+2.88%
